THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Robert Mannel to Sirolimus

Back to Details
This is a "connection" page, showing publications Robert Mannel has written about Sirolimus.
Robert Mannel
Connection Strength
0.090
Sirolimus
  1. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 Oct; 123(1):19-26.
    View in: PubMed
    Score: 0.090
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES